Harmony Biosciences Holdings (HRMY)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Receivables turnover		7.40	7.55	7.47	8.59	7.66	6.96	6.42	7.63	7.72	7.13	7.48
DSO	days	49.34	48.35	48.88	42.51	47.68	52.46	56.83	47.84	47.30	51.18	48.80

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 7.40
= 49.34

To analyze Harmony Biosciences Holdings Inc's Days of Sales Outstanding (DSO) trend, we observe an increase in DSO in Q4 2023 compared to the previous quarter at 46.49 days, which is slightly higher than Q3 2023 at 45.30 days. This indicates that the company is taking a longer time to convert its accounts receivable into cash from sales.

Furthermore, when compared to the same quarter in the previous year, there has been an improvement in DSO as Q4 2023 is lower than Q4 2022 at 45.63 days. This suggests that the company's collections process may have become more efficient over the year.

Overall, the trend in DSO for Harmony Biosciences Holdings Inc shows some variability from quarter to quarter, but the company appears to be managing its accounts receivable effectively, with fluctuations likely influenced by factors such as sales volume, credit policies, and customer payment behavior.